LCM
REGN icon

LCM Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

LCM Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$449K Buy
581
+13
+2% +$9.95K 0.23% 56
2025
Q4 		$438K Sell
568
-7
-1% -$4.75K 0.21% 57
2025
Q3 		$323K Hold
575
– – 0.16% 76
2025
Q2 		$302K Hold
575
– – 0.16% 78
2025
Q1 		$365K Buy
575
+30
+6% +$20.6K 0.21% 64
2024
Q4 		$388K Buy
545
+2
+0.4% +$1.68K 0.22% 64
2024
Q3 		$571K Buy
543
+24
+5% +$26.7K 0.33% 44
2024
Q2 		$545K Buy
519
+29
+6% +$28.1K 0.34% 44
2024
Q1 		$472K Buy
490
+4
+0.8% +$3.8K 0.3% 49
2023
Q4 		$427K Buy
486
+12
+3% +$9.88K 0.31% 48
2023
Q3 		$390K Buy
474
+56
+13% +$44K 0.32% 48
2023
Q2 		$300K Buy
418
+16
+4% +$12.3K 0.24% 61
2023
Q1 		$330K Buy
402
+53
+15% +$40K 0.29% 55
2022
Q4 		$252K Buy
349
+8
+2% +$5.9K 0.25% 62
2022
Q3 		$235K Sell
341
-3
-0.9% -$1.89K 0.25% 63
2022
Q2 		$203K Buy
344
+18
+6% +$11.7K 0.2% 78
2022
Q1 		$228K Buy
+326
New +$206K 0.18% 82

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

LCM Capital Management's REGN Position: Q1 2026 in Review

LCM Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q1 2026, buying an estimated $9.95K and bringing the position to 581 shares worth $449K. The position accounts for 0.23% of the portfolio, ranked #56.

LCM Capital Management first reported a position in REGN in Q1 2022 and has held it in 17 quarters since. The position peaked at $571K in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • LCM Capital Management held 581 shares of Regeneron Pharmaceuticals worth $449K as of Q1 2026.
  • LCM Capital Management bought 13 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $9.95K.
  • Regeneron Pharmaceuticals made up 0.23% of LCM Capital Management's portfolio in Q1 2026, its #56 holding.
  • LCM Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • LCM Capital Management's Regeneron Pharmaceuticals position peaked at $571K in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on LCM Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.